Procaps Group, S.A. (PROC) News
Filter PROC News Items
PROC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROC News Highlights
- PROC's 30 day story count now stands at 2.
- Over the past 11 days, the trend for PROC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest PROC News From Around the Web
Below are the latest news stories about PROCAPS GROUP SA that investors may wish to consider to help them evaluate PROC as an investment opportunity.
Procaps Group Reports Fourth Quarter and Full Year 2022 ResultsMIAMI & BARRANQUILLA, Colombia, May 12, 2023--Procaps Group Reports Fourth Quarter and Full Year 2022 Results |
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F FilingMIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th. The delay in filing the 2022 Form 20-F is because additional time is necessary to prepare and complete the internal review of the Company’s financial statements for the year ended Dece |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning! |
Procaps Issues Shareholder Letter and Provides Preliminary Fiscal Year 2022 Financial Results and 2023 GuidanceReports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences $15MM Cost Reduction Plan to Improve Margins and Financial Performance 20-F & Conference Call for Q4 and FY 2022 Financial Results Expected to Occur in March 2023 MIAMI and BARRANQUILLA, Colombia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leadi |
Procaps Announces Key Changes to the Board of DirectorsInternational Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors MIAMI and BARRANQUILLA, Colombia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the election of Alberto Eguiguren Correa to its Board of Directors. Alberto Eguiguren is an accomplished corporate executive and attorney with board experience including over 20 years in g |
Procaps Group Announces Termination of Acquisition Agreement with Grupo SomarCompany to Provide 2023 Value Creation Plan at J.P. Morgan Healthcare ConferenceMIAMI and BARRANQUILLA, Colombia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the termination of its previously-reported definitive agreement (the “SPA”) to acquire Grupo Somar from the sellers under the SPA. As previously reported, the closing of the acquisition of Grupo Somar |
Procaps to Present at 2023 Annual J.P. Morgan Healthcare ConferenceMIAMI and BARRANQUILLA, Colombia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced that it will present at the 2023 J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:00 am PST. At that time, Procaps will present its 2023 growth plans to investors. Ruben Minski commented “We look forward to updating our investors on our growth plans for 2023. |
Update on Proposed Acquisition of Grupo SomarMIAMI and BARRANQUILLA, Colo., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announces an update on its previously reported definitive agreement, dated as of May 16, 2022 (the “SPA”), to acquire Grupo Somar (including Grupo Farmacéutico Somar, S.A.P.I de C.V., Química y Farmacia S.A. de C.V., Gelcaps Exportadora de Mexico S.A. de C.V. and related entities) from the sellers |
Procaps Group Reports Third Quarter and Nine Months 2022 ResultsConstant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businessesMIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 (“3Q22”) and the nine months ended September 30, 2022 (“9M22”). “Demand remains robu |
Procaps Group to Report Third Quarter and Nine Months of 2022 on November 14, 2022MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:We |